NDCN research underpins new European licence for migraine prevention drug
Novartis receives European licence for Aimovig® (erenumab), the first treatment designed specifically for the prevention of migraine
Read moreGene therapy breakthrough in treating a rare form of blindness
The positive results of the world’s first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in this week’s edition of Nature Medicine.
Read moreYoung people get a taste of working in our labs
Four students were placed in our department as part of the In2Science programme this summer.
Read moreDigital insomnia medicine rolled out as major study links sleep to better health
Millions of people are to be given access to digital treatment for insomnia as an alternative to sleeping pills. Study by Colin Espie et al shows that Sleepio improves wellbeing in nearly three quarters of participants.
Read moreFrom our Head of Department
Welcome to NDCN, one of the leading and largest clinical neuroscience departments in Europe. Our five divisions have all made important discoveries and developed treatments that benefit patients.
Working with us
We are committed to helping all staff and students reach their potential and achieve a good work-life balance.
Take part in our research
What's new
-
Our researchers join in science & ideas festival
5 October 2018
Making a difference
Our research yields practical solutions to many neuroscience-related challenges.
Events
